Glycoconjugate Nanoparticle Vaccines Against Burkholderia Infections
针对伯克霍尔德氏菌感染的糖复合物纳米颗粒疫苗
基本信息
- 批准号:9282736
- 负责人:
- 金额:$ 38.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-01 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAerosolsAnimalsAntibioticsAntigensAreaAttentionBacteriaBiologicalBiological MarkersBiological WarfareBioterrorismBurkholderiaBurkholderia InfectionsBurkholderia malleiBurkholderia pseudomalleiCD4 Positive T LymphocytesCharacteristicsClinicalCoupledCutaneousDNADNA VaccinesDataDevelopmentDiseaseDisease ProgressionDoseEndemic DiseasesFormulationFoundationsGenerationsGlandersGlycoconjugatesGoalsGoldHumanImmuneImmune responseImmunityImmunizationImmunocompromised HostImmunoglobulin GImmunologicsInfectionInflammatoryIngestionLicensingMelioidosisMemory B-LymphocyteModelingMusNatureOpportunistic InfectionsOrganismOutcomePathogenicityPathologyPolysaccharidesPopulationPopulations at RiskPreventionPreventive vaccineProceduresProcessPropertyProteinsPublic HealthResearchSerologicalSerumSystemTestingToxic effectVaccinationVaccinesWhole Cell VaccineWorkbiothreatcapsuleclinically relevantcombatcostcost effectivecytokinediabeticefficacy testingexperimental studyflexibilityhuman diseaseimmunogenicin vivoinnovationinsightmouse modelnanoparticlenanovaccinenovelpathogenpreventtherapeutic vaccinevaccination strategyvaccine developmentweapons
项目摘要
Burkholderia mallei and B. pseudomallei are bacterial pathogens and causative agents of glanders and
melioidosis, respectively. At present, effective vaccines for prevention of glanders or meliodosis have not been
developed. However, renewed attention has been directed toward development of Burkholderia vaccines
because of the pathogens' seemingly ideal characteristics for malicious use as a biowarfare weapon.
Additionally, a vaccine will also have significant value for the immunization of at-risk populations in
melioidosis/glanders endemic areas of the world. Therefore, our long-term goal is to develop a platform that
allows for the efficient generation of a multicomponent vaccine which is able to protect against both glanders
and melioidosis. Our approach will use glycoconjugates coupled to gold nanoparticles (NP) and test their
protective properties in clinically relevant models of infection. The central hypothesis tested indicates that
protein antigens of B. mallei or B. pseudomallei coupled to NP polysaccharides will elicit protection in relevant
mammalian species, and that these antigens will correlate with clinically important serologic/immunologic
readouts. The hypothesis will be evaluated by developing different protein-polysaccharide NPs and comparing
their efficacy in vivo. The flexible NP platform will allow us to additionally incorporate novel antigens identified
by other groups as further enhancing protective immunity. We will establish an optimal immunization procedure
and test the efficacies of protein-polysaccharide NPs in a clinically relevant and highly controlled aerosol
murine model of infection. Finally, we aim to identify the correlates/biomarkers of protection induced by protein-
polysaccharide NP vaccination. This proposal is innovative because it capitalizes on the use of a subunit-NP
vaccine, which could be easily licensable because of its lower cost and more widely disseminated vaccinations
for at-risk populations. Together, these outcomes will help us to identify correlates of protection from protein-
polysaccharide nanoparticles and provide optimized vaccination strategies.
mallei伯克霍尔德氏菌和假芽孢杆菌是腺体和腺体的细菌病原体和病原体
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alfredo G Torres其他文献
Alfredo G Torres的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alfredo G Torres', 18)}}的其他基金
Developing effective nanovaccines against pathogenic Escherichia coli
开发针对致病性大肠杆菌的有效纳米疫苗
- 批准号:
10413247 - 财政年份:2021
- 资助金额:
$ 38.75万 - 项目类别:
Developing effective nanovaccines against pathogenic Escherichia coli
开发针对致病性大肠杆菌的有效纳米疫苗
- 批准号:
10300897 - 财政年份:2021
- 资助金额:
$ 38.75万 - 项目类别:
Defining the role of toxin-antitoxin systems in persistence of Burkholderia pseudomallei
定义毒素-抗毒素系统在类鼻疽伯克霍尔德杆菌持久性中的作用
- 批准号:
10194359 - 财政年份:2020
- 资助金额:
$ 38.75万 - 项目类别:
Glycoconjugate Nanoparticle Vaccines Against Burkholderia Infections
针对伯克霍尔德氏菌感染的糖复合物纳米颗粒疫苗
- 批准号:
9186787 - 财政年份:2016
- 资助金额:
$ 38.75万 - 项目类别:
Vaccine Development for Burkholderia amllei and B. pseudomallei
鼻疽伯克霍尔德杆菌和类鼻疽伯克霍尔德杆菌的疫苗开发
- 批准号:
8377054 - 财政年份:2012
- 资助金额:
$ 38.75万 - 项目类别:
Long Polar Fimbriae of Attaching and Effacing Escherichia coli
附着和消除大肠杆菌的长极菌毛
- 批准号:
7846683 - 财政年份:2009
- 资助金额:
$ 38.75万 - 项目类别:
Long Polar Fimbriae of Attaching and Effacing Escherichia coli
附着和消除大肠杆菌的长极菌毛
- 批准号:
7795038 - 财政年份:2009
- 资助金额:
$ 38.75万 - 项目类别:
Long Polar Fimbriae of Attaching and Effacing Escherichia coli
附着和消除大肠杆菌的长极菌毛
- 批准号:
7662935 - 财政年份:2009
- 资助金额:
$ 38.75万 - 项目类别:
相似海外基金
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
- 批准号:
10092043 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
- 批准号:
2332007 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000021/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000358/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
- 批准号:
DP240100389 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Discovery Projects
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
- 批准号:
83001507 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
- 批准号:
ST/X001091/1 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Research Grant
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
- 批准号:
2326096 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Standard Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
- 批准号:
10080253 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Small Business Research Initiative